Published, Version of Record (VoR)CC BY V4.0, Open
Abstract
Potassium-rich foods might provide many health benefits even to people who have declining renal function. The barrier to obtaining these health benefits has long been the concern over hyperkalemia. There are new and novel treatment options available which may enable patients with chronic kidney disease to obtain the health benefits of eating a diet that contains foods such as fruits and vegetables which are high in potassium while reducing the risk of hyperkalemia. We conclude by emphasizing the need for clinical trials with patients on hemodialysis to directly compare the current standard of care, including a potassium-restricted diet, to a potassium-liberalized diet with a potassium binder. The outcome measures would be serum potassium (<5.3 mmol/L), assessments of acidosis, blood pressure, constipation, glycemic control, overhydration, and azotemia, all of which might change in a favorable direction with vegetarian diets as well as quality of life and satisfaction.
Let Them Eat Healthy: Can Emerging Potassium Binders Help Overcome Dietary Potassium Restrictions in Chronic Kidney Disease?
Creators
Elizabeth J. Sussman - California State University, Northridge
Bhupinder Singh - University of California, Irvine
Deborah Clegg - Drexel University College of Nursing and Health Professions
Biff F. Palmer - The University of Texas Southwestern Medical Center
Kamyar Kalantar-Zadeh - University of California, Irvine
Publication Details
Journal of renal nutrition, v 30(6), pp 475-483
Publisher
Elsevier
Grant note
DaVita
Japanese Society of Dialysis Therapy
AstraZeneca (https://doi.org/10.13039/100004325)
Amgen (https://doi.org/10.13039/100002429)
Shire
Haymarket Media
Vifor (https://doi.org/10.13039/501100006484)
Aveo
International Federation of Kidney Foundations
Keryx
Chugai (https://doi.org/10.13039/100010795)
OPKO
AbbVie (https://doi.org/10.13039/100006483)
Hospira
Veterans' Affairs
International Society of Hemodialysis
Dr. Schär
Abbott (https://doi.org/10.13039/100000046)
Fresenius (https://doi.org/10.13039/501100003389)
Sanofi (https://doi.org/10.13039/100004339)
Genentech (https://doi.org/10.13039/100004328)
Daiichi (https://doi.org/10.13039/501100002336)
Hofstra Medical School
Alexion (https://doi.org/10.13039/100006396)
Kabi
Novartis (https://doi.org/10.13039/100004336)
UpToDate
American Society of Nephrology (https://doi.org/10.13039/100001463)
National Kidney Foundations (https://doi.org/10.13039/100001259)
Relypsa
ZS Pharma
Pfizer (https://doi.org/10.13039/100004319)
National Institutes of Health (https://doi.org/10.13039/100000002)
Akebia
International Society of Renal Nutrition & Metabolism
Kissei
Resverlogix
Sandoz (https://doi.org/10.13039/100011218)
Resource Type
Journal article
Language
English
Web of Science ID
WOS:000590153600004
Scopus ID
2-s2.0-85081253457
Other Identifier
991019357772304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool: